Annexon, Inc.

ANNX Healthcare Biotechnology

In the quarter to June 2026, EPS grew 17.7% and free cash flow fell 26.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.41 0.19 −5.28%
Market cap
$682.5M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Current Ratio
1.68 13.74 9.21 33.33 11.39 11.10 14.72 10.37 5.68
Net Debt/EBITDA
(2.28) 2.37 1.37 5.59 1.89 1.69 1.83 2.05 1.11
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
(1.06) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF/Net income
1.02 0.93 0.74 0.75 0.81 0.82 0.90 0.85 0.89
Capex/Depreciation
0.00 (0.03) (0.54) (0.70) (0.77) (3.10) (0.09) (0.01) (0.06)
ROE
34.04% 33.47% 46.49% (57.69%) (45.24%) (61.30%) (55.73%) (50.84%) (82.63%)
ROA
(67.16%) (76.76%) (78.08%) (34.66%) (40.54%) (49.62%) (46.07%) (42.67%) (66.45%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(392.13%) (41.32%) (89.83%) (20.37%) (53.46%) (58.52%) (51.49%) (46.28%) (99.22%)
Average Days of Receivables
0.00 0.00 0.00 0.00 — — — — —
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(0.50) (42.73) (66.03) (3.16) (2.81) (2.25) (1.60) (0.86) (1.20)
Cash per Share
0.08 109.70 101.34 20.71 6.33 4.44 3.43 2.27 1.54
Shareholders Equity per Share
(1.21) (159.43) (231.73) 20.30 6.05 4.23 3.31 2.13 1.36
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(1.21) (159.43) (231.73) 20.30 6.05 4.23 3.31 2.13 1.36
Free Cash Flow
(19.26) (17.21) (28.62) (53.55) (107.76) (122.83) (121.33) (118.02) (186.49)
Working Capital
1.98 42.38 40.48 343.39 225.95 225.74 245.93 285.95 199.56
Capital Expenditures
(0.57) (0.02) (0.27) (0.46) (1.65) (6.53) (0.19) (0.01) (0.14)
Net Current Asset Value
(49.14) (66.64) (104.95) 342.34 192.56 194.20 216.74 259.50 176.27
Other line items
Quick Ratio
1.22 13.28 8.91 33.06 11.16 10.85 14.49 10.23 5.59
Depreciation/Fixed assets
0.10 0.21 0.23 0.34 0.12 0.13 0.15 0.17 0.20
Cash ROIC
(336.36%) 85.92% 50.64% (7.70%) (22.71%) (25.92%) (23.78%) (19.50%) (41.44%)
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 — — — — —
Accounts Payable Turnover
0.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 — — —
Average Days of Payables
2,052.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
0.00 0.00 0.00 0.00 0.00 0.00 — — —
Revenue per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF per Share
(0.50) (42.69) (65.42) (3.13) (2.77) (2.13) (1.60) (0.86) (1.20)
Capex per Share
0.00 (0.04) (0.62) (0.03) (0.04) (0.12) 0.00 0.00 0.00
Average Receivables
0.40 0.40 0.15 0.04 — — — — —
Average Payables
1.40 1.40 1.82 3.05 7.44 9.28 6.45 7.96 12.68
Average Assets
27.99 24.07 49.02 202.92 321.49 286.07 291.39 323.87 313.82
Average Common Equity
(55.21) (55.21) (82.33) 121.91 288.09 231.55 240.88 271.83 252.38
Capex to Sales
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates